Mr. John McMullen reports

LGC TO FOCUS ON INVESTMENTS IN NEAR-TERM MEDICAL CANNABIS PRODUCTION

LGC Capital Ltd. has formally terminated its option to acquire a 30-per-cent interest in South Africa-based House of Hemp Pty. Ltd. in favour of focusing LGC's resources and cash-strong balance sheet on developing its fast-growing investments in Australia, Montreal, Jamaica and Europe. LGC also announces that it is examining new near-term cash-flowing investment opportunities in Europe and Southern Africa. As previously announced, LGC's 50/50 joint venture with AfriAg Pty. Ltd. had the exclusive right to acquire a 60-per-cent interest in House of Hemp.

The South African government has not put in place the legislative framework for the legalization of medical cannabis in that country. Although House of Hemp is still actively seeking a full set of commercial licences, its lack of licences at present means that it does not meet LGC's strict criteria for near-term production and cash flow.

As a result, House of Hemp no longer fits with LGC's investment objectives. LGC has a number of other investment opportunities that it believes will offer better short-term returns for its shareholders. The amounts invested by LGC in its due diligence review of House of Hemp were not material.

John McMullen, LGC's chief executive officer, commented: "LGC has a number of very exciting projects that are now moving rapidly toward commercial medical cannabis production. These businesses are LGC's prime focus. We are looking forward to Little Green Pharma harvesting its first commercial crop in Australia in the next few weeks, and AAA Trichomes breaking ground at its new facility in Montreal over the coming weeks. In addition, LGC is working hard with the Global Canna Labs team in Jamaica to complete our detailed due diligence and assist its management team with its first commercial planting expected to commence next month. Italy's Evolution Bnk, which already has a cash flow, is on track to begin planting its first cannabis crops this summer. Our investments in Little Green Pharma and AAA Trichomes and our pending investments in Global Canna Labs and Evolution Bnk, in Australia, Canada, Jamaica and Italy, all have the potential for significant production of medical cannabis as each operation grows. Our CLV Frontier Brands joint venture with Creso Pharma Ltd. and Baltic Beer Company Ltd. is on track to be in full commercial production and distribution this summer."

Mr. McMullen continued: "With respect to terminating the House of Hemp transaction, the absence of medical cannabis legislation in South Africa unfortunately means that House of Hemp's business is no longer one that suits LGC's business objectives of investing in near-term cash-flowing businesses. Not every investment LGC investigates will be concluded, and if businesses do not 100 per cent stack-up for any reason whatsoever with respect to due diligence, budgets, timing or production potential, LGC will walk away from these opportunities to focus on better suited investment opportunities around the globe that meet our strict investment criteria."

Closing of LGC's transactions with Global Canna Labs and Evolution Bnk, respectively, is subject to the parties entering into definitive agreements, standard closing conditions and regulatory approval, including that of the TSX Venture Exchange.

About LGC Capital Ltd.

LGC Capital is a Canadian incorporated public company listed on the TSX Venture Exchange. LGC's objective is to become a diversified business group with core business divisions that provide shareholders with exposure to a diverse range of businesses, products and services.

We seek Safe Harbor.